Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy

Richard T. Davey, Peter E. Pertel, Alice Benson, Delanie J. Cassell, Brian G. Gazzard, Mark Holodniy, Jacob P. Lalezari, Yves Levy, Ronald T. Mitsuyasu, Frank J. Palella, Richard B Pollard, Prabhu Rajagopalan, Michael S. Saag, Robert A. Salata, Beverly E. Sha, Shurjeel Choudhri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We sought to determine the safety, maximum tolerated dose, optimal dose, and preliminary dose efficacy of intermittent subcutaneously (s.c.) administered BAY 50-4798 among patients with HIV infection receiving highly active antiretroviral therapy (HAART) compared with patients receiving HAART alone. A phase I/II randomized, double-blind, dose-escalation study was conducted of the safety, tolerability, pharmacokinetics, and efficacy of s.c. BAY 50-4798 administered to HIV-infected patients already receiving stable HAART. There were no unexpected safety findings in a population of HIV-infected patients receiving HAART plus SC BAY 50-4798 as adjunctive therapy. BAY 50-4798 exhibited nearly dose-proportional pharmacokinetics, and accumulation was minimal during multiple-dose treatment. Limited efficacy data indicated that treatment with BAY 50-4798 caused at least a transient increase in CD4+ T cell counts in some recipients, particularly at the early time points. In general, this effect appeared to increase with increasing dose. Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary.

Original languageEnglish (US)
Pages (from-to)89-100
Number of pages12
JournalJournal of Interferon and Cytokine Research
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Highly Active Antiretroviral Therapy
Interleukin-2
Pharmacokinetics
HIV
Safety
Maximum Tolerated Dose
CD4 Lymphocyte Count
HIV Infections
Appointments and Schedules
Therapeutics
aldesleukin
T-Lymphocytes
Population

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. / Davey, Richard T.; Pertel, Peter E.; Benson, Alice; Cassell, Delanie J.; Gazzard, Brian G.; Holodniy, Mark; Lalezari, Jacob P.; Levy, Yves; Mitsuyasu, Ronald T.; Palella, Frank J.; Pollard, Richard B; Rajagopalan, Prabhu; Saag, Michael S.; Salata, Robert A.; Sha, Beverly E.; Choudhri, Shurjeel.

In: Journal of Interferon and Cytokine Research, Vol. 28, No. 2, 01.02.2008, p. 89-100.

Research output: Contribution to journalArticle

Davey, RT, Pertel, PE, Benson, A, Cassell, DJ, Gazzard, BG, Holodniy, M, Lalezari, JP, Levy, Y, Mitsuyasu, RT, Palella, FJ, Pollard, RB, Rajagopalan, P, Saag, MS, Salata, RA, Sha, BE & Choudhri, S 2008, 'Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy', Journal of Interferon and Cytokine Research, vol. 28, no. 2, pp. 89-100. https://doi.org/10.1089/jir.2007.0064
Davey, Richard T. ; Pertel, Peter E. ; Benson, Alice ; Cassell, Delanie J. ; Gazzard, Brian G. ; Holodniy, Mark ; Lalezari, Jacob P. ; Levy, Yves ; Mitsuyasu, Ronald T. ; Palella, Frank J. ; Pollard, Richard B ; Rajagopalan, Prabhu ; Saag, Michael S. ; Salata, Robert A. ; Sha, Beverly E. ; Choudhri, Shurjeel. / Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. In: Journal of Interferon and Cytokine Research. 2008 ; Vol. 28, No. 2. pp. 89-100.
@article{fc3638b8c41a4aaf9fa6270357d89523,
title = "Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy",
abstract = "We sought to determine the safety, maximum tolerated dose, optimal dose, and preliminary dose efficacy of intermittent subcutaneously (s.c.) administered BAY 50-4798 among patients with HIV infection receiving highly active antiretroviral therapy (HAART) compared with patients receiving HAART alone. A phase I/II randomized, double-blind, dose-escalation study was conducted of the safety, tolerability, pharmacokinetics, and efficacy of s.c. BAY 50-4798 administered to HIV-infected patients already receiving stable HAART. There were no unexpected safety findings in a population of HIV-infected patients receiving HAART plus SC BAY 50-4798 as adjunctive therapy. BAY 50-4798 exhibited nearly dose-proportional pharmacokinetics, and accumulation was minimal during multiple-dose treatment. Limited efficacy data indicated that treatment with BAY 50-4798 caused at least a transient increase in CD4+ T cell counts in some recipients, particularly at the early time points. In general, this effect appeared to increase with increasing dose. Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary.",
author = "Davey, {Richard T.} and Pertel, {Peter E.} and Alice Benson and Cassell, {Delanie J.} and Gazzard, {Brian G.} and Mark Holodniy and Lalezari, {Jacob P.} and Yves Levy and Mitsuyasu, {Ronald T.} and Palella, {Frank J.} and Pollard, {Richard B} and Prabhu Rajagopalan and Saag, {Michael S.} and Salata, {Robert A.} and Sha, {Beverly E.} and Shurjeel Choudhri",
year = "2008",
month = "2",
day = "1",
doi = "10.1089/jir.2007.0064",
language = "English (US)",
volume = "28",
pages = "89--100",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy

AU - Davey, Richard T.

AU - Pertel, Peter E.

AU - Benson, Alice

AU - Cassell, Delanie J.

AU - Gazzard, Brian G.

AU - Holodniy, Mark

AU - Lalezari, Jacob P.

AU - Levy, Yves

AU - Mitsuyasu, Ronald T.

AU - Palella, Frank J.

AU - Pollard, Richard B

AU - Rajagopalan, Prabhu

AU - Saag, Michael S.

AU - Salata, Robert A.

AU - Sha, Beverly E.

AU - Choudhri, Shurjeel

PY - 2008/2/1

Y1 - 2008/2/1

N2 - We sought to determine the safety, maximum tolerated dose, optimal dose, and preliminary dose efficacy of intermittent subcutaneously (s.c.) administered BAY 50-4798 among patients with HIV infection receiving highly active antiretroviral therapy (HAART) compared with patients receiving HAART alone. A phase I/II randomized, double-blind, dose-escalation study was conducted of the safety, tolerability, pharmacokinetics, and efficacy of s.c. BAY 50-4798 administered to HIV-infected patients already receiving stable HAART. There were no unexpected safety findings in a population of HIV-infected patients receiving HAART plus SC BAY 50-4798 as adjunctive therapy. BAY 50-4798 exhibited nearly dose-proportional pharmacokinetics, and accumulation was minimal during multiple-dose treatment. Limited efficacy data indicated that treatment with BAY 50-4798 caused at least a transient increase in CD4+ T cell counts in some recipients, particularly at the early time points. In general, this effect appeared to increase with increasing dose. Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary.

AB - We sought to determine the safety, maximum tolerated dose, optimal dose, and preliminary dose efficacy of intermittent subcutaneously (s.c.) administered BAY 50-4798 among patients with HIV infection receiving highly active antiretroviral therapy (HAART) compared with patients receiving HAART alone. A phase I/II randomized, double-blind, dose-escalation study was conducted of the safety, tolerability, pharmacokinetics, and efficacy of s.c. BAY 50-4798 administered to HIV-infected patients already receiving stable HAART. There were no unexpected safety findings in a population of HIV-infected patients receiving HAART plus SC BAY 50-4798 as adjunctive therapy. BAY 50-4798 exhibited nearly dose-proportional pharmacokinetics, and accumulation was minimal during multiple-dose treatment. Limited efficacy data indicated that treatment with BAY 50-4798 caused at least a transient increase in CD4+ T cell counts in some recipients, particularly at the early time points. In general, this effect appeared to increase with increasing dose. Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary.

UR - http://www.scopus.com/inward/record.url?scp=39449086420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449086420&partnerID=8YFLogxK

U2 - 10.1089/jir.2007.0064

DO - 10.1089/jir.2007.0064

M3 - Article

VL - 28

SP - 89

EP - 100

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 2

ER -